Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Clin Pharm Ther ; 43(5): 723-725, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29733112

RESUMEN

WHAT IS KNOWN AND OBJECTIVE: The interaction between valproic acid (VPA) and carbapenem antibiotics is well described with previous reports suggesting a reduction in VPA half-life between 47% and 90%. As described in this case, this interaction might be beneficial in the setting of toxic VPA ingestion. CASE DESCRIPTION: An intubated, unresponsive patient arrived via emergency medical services after toxic VPA ingestion. Meropenem was prescribed for a suspected pneumonia and to take advantage of the VPA interaction. We observed a 56% decline in half-life with short-term meropenem dosing and an improvement in mental status shortly after administration. WHAT IS NEW AND CONCLUSION: Our findings suggest a potential role for short-term carbapenem therapy for VPA overdose.


Asunto(s)
Anticonvulsivantes/efectos adversos , Carbapenémicos/uso terapéutico , Ácido Valproico/efectos adversos , Interacciones Farmacológicas/fisiología , Humanos , Masculino , Meropenem/uso terapéutico , Persona de Mediana Edad
2.
Clin Toxicol (Phila) ; 59(11): 1023-1026, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-33703984

RESUMEN

INTRODUCTION: Anavip (F(ab')2AV) is a lyophilized F(ab')2 immunoglobulin fragment derived from horses immunized with venom from Bothrops asper and Crotalus durissus. It was approved by the FDA in 2015 for treatment of North American rattlesnake envenomation but not for Agkistrodon envenomation. Published data regarding the efficacy and safety of Anavip in treating Agkistrodon envenomations is limited. We present a case of a patient treated with Anavip after confirmed Agkistrodon laticinctus envenomation. CASE DETAILS: A 77 year-old man was bitten on his fifth finger by a captive A. laticinctus. He was taken to a local emergency department where he received a 10 vial initial dose of F(ab')2AV for pain and swelling and was transferred. At the receiving facility, his pain had improved and his swelling had not progressed. Over the next 30 h, his platelets declined to 132,000/mm3 and he received an additional 4 vials of F(ab')2AV. The remainder of his course was unremarkable with complete recovery by 3 months. DISCUSSION: This case provides an additional published datapoint on the use of this F(ab')2AV in the treatment of envenomation by Agkistrodon.


Asunto(s)
Agkistrodon , Antivenenos/uso terapéutico , Venenos de Crotálidos/antagonistas & inhibidores , Fragmentos Fab de Inmunoglobulinas/uso terapéutico , Mordeduras de Serpientes/tratamiento farmacológico , Anciano , Agkistrodon/metabolismo , Animales , Antivenenos/efectos adversos , Venenos de Crotálidos/metabolismo , Humanos , Fragmentos Fab de Inmunoglobulinas/efectos adversos , Masculino , Mordeduras de Serpientes/diagnóstico , Mordeduras de Serpientes/metabolismo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA